Axon Enterprise, Inc $AXON Shares Acquired by Ampersand Capital Group L.P.

Ampersand Capital Group L.P. boosted its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 47.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,156 shares of the biotechnology company’s stock after purchasing an additional 15,450 shares during the period. Axon Enterprise comprises about 11.2% of Ampersand Capital Group L.P.’s holdings, making the stock its 6th largest holding. Ampersand Capital Group L.P.’s holdings in Axon Enterprise were worth $20,451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new stake in shares of Axon Enterprise during the second quarter worth $37,000. Creative Financial Designs Inc. ADV acquired a new position in shares of Axon Enterprise during the fourth quarter worth $28,000. Sound Income Strategies LLC lifted its stake in shares of Axon Enterprise by 550.0% in the 4th quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 44 shares during the last quarter. Camelot Portfolios LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at $30,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at $34,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AXON shares. The Goldman Sachs Group set a $535.00 price objective on Axon Enterprise in a research report on Thursday, May 7th. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 10th. Needham & Company LLC lifted their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research note on Monday, July 6th. Royal Bank Of Canada restated an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, July 21st. Finally, JPMorgan Chase & Co. upped their price objective on Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Fifteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $725.25.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $502.34 on Monday. The firm has a market capitalization of $40.49 billion, a PE ratio of 201.74, a price-to-earnings-growth ratio of 10.25 and a beta of 1.38. The business’s 50-day moving average price is $483.26 and its two-hundred day moving average price is $478.81. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. Axon Enterprise, Inc has a 12 month low of $339.01 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The company had revenue of $807.35 million during the quarter, compared to the consensus estimate of $778.90 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm’s revenue was up 33.7% compared to the same quarter last year. During the same period last year, the company earned $1.47 earnings per share. On average, analysts expect that Axon Enterprise, Inc will post 1.63 EPS for the current year.

Insider Buying and Selling at Axon Enterprise

In other news, CRO Cameron Brooks sold 1,242 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total value of $621,000.00. Following the transaction, the executive owned 49,710 shares in the company, valued at approximately $24,855,000. The trade was a 2.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total transaction of $753,690.00. Following the completion of the sale, the insider directly owned 34,024 shares in the company, valued at approximately $16,501,640. This represents a 4.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 58,989 shares of company stock worth $30,527,983. Company insiders own 4.20% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.